Biotechnology industries
Procyon Biopharma Inc. and IMI International Medical Innovations Inc. have expressed their shared excitement over the progress made in the study of ColorectAlert, a patented test for the early detection of colorectal cancer. The test involves analyzing a sample of rectal mucus taken during a routine doctor visit, which is
Biotechnology industries
The Techcenter@UMBC Incubator Program has welcomed a new biotechnology start-up, Lentigen Corp, which aims to revolutionize gene therapy by delivering genetic material into cells to cure genetic disorders. Lentigen's chief executive officer, Boro Dropulic, explained that gene therapy allows doctors and scientists to target the causes of
Biotechnology industries
Aastrom Biosciences, Inc. (ASTM), a leader in the development of patient-specific products for tissue repair and regeneration, has announced its inclusion in the Russell 3000 Index. This significant milestone for the company marks its recognition as one of the 3,000 largest U.S. companies based on total market capitalization.
Biotechnology industries
Seattle Genetics, Inc. has licensed its proprietary antibody-drug conjugate (ADC) technology to PSMA Development Company LLC, a joint venture between Progenics Pharmaceuticals, Inc. and Cytogen Corporation. This multi-year agreement provides PDC with access to the ADC technology for use with antibodies targeting prostate-specific membrane antigen (PSMA), a protein highly expressed
Biotechnology industries
Researchers at Generex Biotechnology's subsidiary, Antigen Express, Inc., have made significant strides in developing a novel approach to controlling both fatal and disabling allergic reactions. A research collaboration agreement with Stallergenes, SA, a major European firm in immunological treatments for allergy and asthma, aims to design and test
Biotechnology industries
Cincinnati-based companies Cintas (NASDAQ:CTAS) and W.W. Grainger (NYSE:GWW) led the pack among the stocks featured in the July 15 edition of Schaeffer's S&P 500 Index Hot Stocks. Cintas reported fourth-quarter earnings of 48 cents per share, topping last year's same-quarter earnings
Biotechnology industries
Jul 14, 2005 saw a mixed bag of stock performances as several companies reported their earnings and guidance, causing significant fluctuations in the market. General Motors Corporation, Taser International Inc., and Genzyme Corporation were among those that saw their stocks rise after reporting positive results. On the other hand, Allscripts
Pharmaceutical industry
A recent clinical trial of Rituxan (Rituximab) in rheumatoid arthritis (RA) has yielded positive results, demonstrating a greater proportion of patients achieving American College of Rheumatology (ACR) 20, 50, and 70 response rates compared to placebo. The trial, known as the dose-ranging assessment international clinical evaluation of Rituximab in RA
Pharmaceutical industry
Oral-lyn, a proprietary oral insulin spray formulation, has shown promising results in a recent study conducted by a team of diabetes investigators from Hadassah Hebrew University Hospital in Israel. The study, published in the June 2005 issue of Diabetes Care, aimed to evaluate the pharmacodynamic and pharmacokinetic properties of Oral-lyn
Biotechnology industries
As larger pharmaceutical companies retreat from the hospital antibiotics market, smaller companies like Cubist, Vicuron, Basilea, and Novexel are positioned to establish niches in this arena. Decision Resources, Inc., reports that large pharmaceutical companies, such as Roche, Wyeth, Pfizer, Johnson & Johnson, Merck, and GlaxoSmithKline, have dominated the market but
Biotechnology industries
MDS Nordion and Macrocyclics Inc. have announced a three-year research and development collaboration to develop innovative bifunctional chelates for use in molecular imaging and targeted therapeutic pharmaceuticals. This partnership aims to create novel chelate structures, linkers, and conjugation methods that will enable researchers to use a wider range of targeting
Biotechnology industries
Advanced Viral Research Corp. (ADVR) has successfully secured patent #ZL 00811493.5 in China for its flagship product AVR118, a biopolymer with novel immunomodulatory activity. This patent, titled "Preparation of a Therapeutic Composition," complements ADVR's existing intellectual property estate and provides additional protection for AVR118. The
